The prevalence of rare diseases has surged in recent years, as the tracking of their incidence has improved around the world in the past few decades. This is particularly significant for genetic diseases, as standardized screenings and tests are few, as such, making it hard to determine how many people are affected by them. Hereditary angioedema, also known as HAE, has been in the spotlight, as government and non-government organizations around the world work to raise public awareness to increase diagnosis and improve treatment. According to a report by Transparency Market Research on the global hereditary angioedema treatment market, in 2018, the treatment for HAE was sought mainly in North America, making it the largest regional market, accounting for over three-fourth of the global market share. This can be attributed not only to enhanced data tracking, but also better healthcare infrastructure, which has led to the better availability of specialty HAE products in the region.
Although the North America market is expected to grow at a healthy pace over the forecast years, it is expected to yield market share of ~4% to Europe and the Rest of the World, as public awareness about the disease rises in other parts of the world, shaping the further evolution of the hereditary angioedema treatment market.
The intravenous route of medicine administration has been the method of choice for drugs used in the treatment of hereditary angioedema. This can be attributed to the fact that, conventional prophylactic drugs have traditionally been administered intravenously, and this method has occupied a significant share of the global hereditary angioedema treatment market in the last few years. However, with the development of drugs that can be administered orally and by subcutaneous injection, intravenous drugs are expected to lose popularity in the foreseeable future.
The phenomenal growth of subcutaneous injections as a mode of drug administration can be attributed to the demand for ease-of-usage for patients, which has had an instrumental impact on the growth of this segment. Where in 2018 subcutaneous injections accounted for close to half of the total market, by the end of the forecast period in 2027, this segment is anticipated to grow to occupy ~65% of the share.
In recent years, there has been an impressive amount of research being done for the development of drugs for hereditary angioedema treatment. This has included not just drugs to control the symptoms of the illness, but also prophylactic treatment for HAE attacks. There are currently several drugs that are in various stages of approval for the long-term prophylactic treatment of HAE in children and adults. For instance, in May 2019, BioCryst Pharmaceuticals announced that its drug - BCX7353, for the prevention of (HAE) attacks, has achieved its primary endpoint for both dose levels.
Frequent Misdiagnosis of HAE to Negatively Impact Market
As with all rare genetic diseases, because the incidence of hereditary angioedema is lower in comparison to other illnesses, it is often overlooked and misdiagnosed as a different disease. The alarming rate of misdiagnosis of hereditary angioedema, globally, as common allergies, appendicitis, and Irritable Bowel Syndrome, has led to a delay in effective treatment, which has had a significant negative impact on the growth of the global hereditary angioedema treatment market.
Also restraining the growth of the market is the prohibitively high cost of the drugs used for hereditary angioedema treatment. Even as drug companies are working to introduce newer and better drugs for hereditary angioedema treatment, for both, acute attack and prophylactic treatments, cost management continues to remain an obstacle in the growth trajectory of the market.
Hereditary Angioedema Treatment Market: Analysts’ Overview
The global hereditary angioedema treatment market is set to grow at a healthy pace during the forecast period, due to the gradually increasing awareness and diagnoses of rare genetic diseases, and product innovation for their treatment. According to analysts at Transparency Market Research, as newer and better classes of drugs are being made for a spectrum of symptoms and severity, players targeting their R&D toward the prophylactic treatment of hereditary angioedema attacks are likely to maximize their gains in the near future.
Subcutaneous injections are growing in popularity due to patient convenience and ease, being aided by the launch of innovative new products that employ this route of administration. Players in the market taking advantage of this preference in the development of medication for HAE are likely to gain a competitive edge in the hereditary angioedema treatment market.
The regional market in North America is expected to expand robustly, due to the large number of reported cases, coupled with a well-established healthcare infrastructure. The future is set to be lucrative for manufacturers focusing on ameliorating their product offerings to include personalized and speciality drugs for the treatment of hereditary angioedema.
Global Hereditary Angioedema Treatment Market and Report Description
Hereditary Angioedema Treatment Market: Drivers
Hereditary Angioedema Treatment Market: Notable Trends
Hereditary Angioedema Treatment Market: Segment Analysis
Global Hereditary Angioedema Treatment Market: Major Players
Hereditary angioedema treatment market to Reach a value of ~US$ 5 Bn by 2027
Hereditary angioedema treatment market is projected to expand at a CAGR of ~9% from 2019 to 2027
Hereditary angioedema treatment market is driven by increase in awareness about hereditary angioedema and novel pipeline drugs
The subcutaneous injection segment dominated the global market, and the trend is likely to continue during the forecast period
Key players in the global hereditary angioedema treatment market are Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group NV
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hereditary Angioedema Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Pipeline Analysis
5.2. Orphan Drug Exclusivity Scenario
5.3. Key Merger & Acquisitions
5.4. Disease Overview
5.5. Disease Prevalence-Global and Key Countries
6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017–2027
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. C1 Esterase Inhibitor
6.3.1.1. Plasma Products
6.3.1.1.1. Berinert
6.3.1.1.2. Cinryze
6.3.1.1.3. Haegarda
6.3.1.2. Recombinant Products
6.3.1.2.1. Ruconest
6.3.2. Selective Bradykinin B2 Receptor Antagonist
6.3.2.1. Firazyr
6.3.3. Kallikrein Inhibitor
6.3.3.1. Kalbitor
6.3.3.2. Takhzyro
6.3.4. Others
6.3.4.1. Conventional Drugs
6.3.4.2. Pipeline Drugs
6.4. Market Attractiveness By Drug Class
7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017–2027
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2027
7.3.1. Intravenous
7.3.2. Subcutaneous Injection
7.3.3. Oral
7.4. Market Attractiveness, by Route of Administration
8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017–2027
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness, by Distribution Channel
9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017–2027
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Rest of the World
9.3. Market Attractiveness, by Country/Region
10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. C1 Esterase Inhibitor
10.2.1.1. Plasma Products
10.2.1.1.1. Berinert
10.2.1.1.2. Cinryze
10.2.1.1.3. Haegarda
10.2.1.2. Recombinant Products
10.2.1.2.1. Ruconest
10.2.2. Selective Bradykinin B2 Receptor Antagonist
10.2.2.1. Firazyr
10.2.3. Kallikrein Inhibitor
10.2.3.1. Kalbitor
10.2.3.2. Takhzyro
10.2.4. Others
10.2.4.1. Conventional Drugs
10.2.4.2. Pipeline Drugs
10.3. Market Value Forecast, by Route of Administration, 2017–2027
10.3.1. Intravenous
10.3.2. Subcutaneous Injection
10.3.3. Oral
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
11.1. .Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. C1 Esterase Inhibitor
11.2.1.1. Plasma Products
11.2.1.1.1. Berinert
11.2.1.1.2. Cinryze
11.2.1.1.3. Haegarda
11.2.1.2. Recombinant Products
11.2.1.2.1. Ruconest
11.2.2. Selective Bradykinin B2 Receptor Antagonist
11.2.2.1. Firazyr
11.2.3. Kallikrein Inhibitor
11.2.3.1. Kalbitor
11.2.3.2. Takhzyro
11.2.4. Others
11.2.4.1. Conventional Drugs
11.2.4.2. Pipeline Drugs
11.3. Market Value Forecast, by Route of Administration, 2017–2027
11.3.1. Intravenous
11.3.2. Subcutaneous Injection
11.3.3. Oral
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. C1 Esterase Inhibitor
12.2.1.1. Plasma Products
12.2.1.1.1. Berinert
12.2.1.1.2. Cinryze
12.2.1.1.3. Haegarda
12.2.1.2. Recombinant Products
12.2.1.2.1. Ruconest
12.2.2. Selective Bradykinin B2 Receptor Antagonist
12.2.2.1. Firazyr
12.2.3. Kallikrein Inhibitor
12.2.3.1. Kalbitor
12.2.3.2. Takhzyro
12.2.4. Others
12.2.4.1. Conventional Drugs
12.2.4.2. Pipeline Drugs
12.3. Market Value Forecast, by Route of Administration, 2017–2027
12.3.1. Intravenous
12.3.2. Subcutaneous Injection
12.3.3. Oral
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Distribution Channel
13. Competitive Landscape
13.1. Market Player - Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis, by Company, 2018
13.3. Company Profiles
13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Company Financials
13.3.1.3. Growth Strategies
13.3.1.4. SWOT Analysis
13.3.2. CSL Limited
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Company Financials
13.3.2.3. Growth Strategies
13.3.2.4. SWOT Analysis
13.3.3. Pharming Group N.V.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Company Financials
13.3.3.3. Growth Strategies
13.3.3.4. SWOT Analysis
13.3.4. Ionis Pharmaceuticals, Inc.
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Company Financials
13.3.4.3. Growth Strategies
13.3.4.4. SWOT Analysis
13.3.5. BioCryst Pharmaceuticals, Inc.
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Company Financials
13.3.5.3. Growth Strategies
13.3.5.4. SWOT Analysis
13.3.6. KalVista Pharmaceuticals Ltd.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Company Financials
13.3.6.3. Growth Strategies
13.3.6.4. SWOT Analysis
13.3.7. Attune Pharmaceuticals
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Company Financials
13.3.7.3. Growth Strategies
13.3.7.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, by Phase II and Phase I
Table 03: Pipeline Analysis, by Preclinical Trial
Table 04: Orphan Drug Exclusivity
Table 05: Key Mergers & Acquisition in the Hereditary Angioedema Treatment Market
Table 06: Disease Overview by Type of HAE
Table 07: Reported and Estimated Cases of HAE, by Country
Table 08: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 13: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 14: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 16: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 17: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 18: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 19: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 20: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 21: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 22: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 23: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 26: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 27: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 28: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 29: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 30: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 31: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 33: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027
Table 34: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027
Table 35: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027
Table 36: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027
Table 37: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 38: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global Hereditary Angioedema Treatment Market Value Share, by Drug Class, 2018
Figure 04: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018
Figure 05: Global Hereditary Angioedema Treatment Market Value Share, by Distribution Channel, 2018
Figure 06: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018
Figure 07: Global Hereditary Angioedema Treatment Market - Key Drivers and Restraints
Figure 08: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2017–2027
Figure 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2017–2027
Figure 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2017–2027
Figure 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 13: Global Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 14: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2017–2027
Figure 16: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2017–2027
Figure 17: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027
Figure 18: Global Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 19: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 20: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 21: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 22: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 23: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 24: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 25: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 26: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 27: North America Hereditary Angioedema Treatment Market Value Share, by Country, 2018 and 2027
Figure 28: North America Hereditary Angioedema Treatment Market Attractiveness, by Country, 2019–2027
Figure 29: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 30: North America Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 31: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 32: North America Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 33: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 34: North America Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 35: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 36: Europe Hereditary Angioedema Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 37: Europe Hereditary Angioedema Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 38: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 39: Europe Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 40: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 41: Europe Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 42: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 43: Europe Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 44: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027
Figure 45: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 46: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 47: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 48: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 49: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 50: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 51: Global Hereditary Angioedema Treatment Market Share Analysis, by Company (2018)
Figure 52: Shire plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 53: Shire plc, Breakdown of Net Sales (%), by Geography, 2017
Figure 54: Shire plc, Breakdown of Net Sales (%), by Therapeutic areas, 2017
Figure 55: Shire plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 56: CSL Behring, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 57: CSL Behring, Breakdown of Net Sales (%), by Geography, 2018
Figure 58: CSL Behring, Breakdown of Net Sales (%), by Product Division/Therapy, 2018
Figure 59: CSL Limited, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 60: Pharming Group NV, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 61: Pharming Group NV, Breakdown of Net Sales (%), by Geography, 2018
Figure 62: Pharming Group NV, Region-wise Breakdown of Net Sales (%), by Ruconest, 2018
Figure 63: Pharming Group NV, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 64: Ionis Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 65: Ionis Pharmaceuticals, Inc., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 66: Ionis Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 67: BioCryst Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 68: BioCryst Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 69: KalVista Pharmaceuticals Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 70: KalVista Pharmaceuticals Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hereditary Angioedema Treatment Market
